Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q07699: Variant p.Arg125Leu

Sodium channel regulatory subunit beta-1
Gene: SCN1B
Feedback?
Variant information Variant position: help 125 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Leucine (L) at position 125 (R125L, p.Arg125Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In GEFSP1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 125 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 218 The length of the canonical sequence.
Location on the sequence: help SIFITNVTYNHSGDYECHVY R LLFFENYEHNTSVVKKIHIE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         SIFITNVTYNHSGDYECHVYRLLFFENYEHNTSVVKKIHIE

                              SIFITNVTYNHSGDYECHVYRLLFFENYEHNTSVVKKIHIE

Chimpanzee                    SIFITNVTYNHSGDYECHVYRLLFFENYEHNTSVVKKIHIE

Mouse                         SIFITNVTYNHSGDYECHVYRLLFFDNYEHNTSVVKKIHLE

Rat                           SIFITNVTYNHSGDYECHVYRLLFFDNYEHNTSVVKKIHLE

Bovine                        SIFITNVTYNHSGDYECHVYRLLFFDNYEHNTSVVKKIHLE

Rabbit                        SIFITNVTYNHSGDYQCHVYRLLSFENYEHNTSVVKKIHLE

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 19 – 218 Sodium channel regulatory subunit beta-1
Topological domain 19 – 157 Extracellular
Domain 22 – 150 Ig-like C2-type
Glycosylation 110 – 110 N-linked (GlcNAc...) asparagine
Glycosylation 114 – 114 N-linked (GlcNAc...) asparagine
Glycosylation 135 – 135 N-linked (GlcNAc...) asparagine
Beta strand 117 – 128



Literature citations
New mutation c.374C>T and a putative disease-associated haplotype within SCN1B gene in Tunisian families with febrile seizures.
Fendri-Kriaa N.; Kammoun F.; Salem I.H.; Kifagi C.; Mkaouar-Rebai E.; Hsairi I.; Rebai A.; Triki C.; Fakhfakh F.;
Eur. J. Neurol. 18:695-702(2011)
Cited for: VARIANT GEFSP1 LEU-125;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.